Analyst Price Target is $3.83
▲ +110.62% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for ZIOPHARM Oncology in the last 3 months. The average price target is $3.83, with a high forecast of $5.00 and a low forecast of $3.00. The average price target represents a 110.62% upside from the last price of $1.82.
Current Consensus is
The current consensus among 4 investment analysts is to hold stock in ZIOPHARM Oncology. This rating has held steady since February 2020, when it changed from a Buy consensus rating.
ZIOPHARM Oncology, Inc. is a biopharmaceutical company, which engages in the development, acquisition, and commercialization of immuno-oncology platforms that leverage cell- and gene-based therapies to treat patients with cancer. Its pipeline includes Sleeping Beauty TCR-T Targeting neoantigens; Ad-RTS-hlL-12 + veledimex; and Sleeping Beauty CAR-T. The company was founded on September 9, 2003 and is headquartered in Boston, MA.